Last reviewed · How we verify
GLP-1 receptor antagonist
At a glance
| Generic name | GLP-1 receptor antagonist |
|---|---|
| Sponsor | Amsterdam UMC, location VUmc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery (PHASE1)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Avexitide for Treatment of Post-Bariatric Hypoglycemia (PHASE3)
- Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. (PHASE1)
- The MICRON Study - A Steno 1 Substudy
- The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans (PHASE2)
- The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes (NA)
- Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-1 receptor antagonist CI brief — competitive landscape report
- GLP-1 receptor antagonist updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI